Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Malaria Pipeline Review H2 2016: Stage of Development and Molecule Type Analysis

Wednesday, November 30, 2016 3:21
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Malaria Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Malaria therapeutics industry report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

 

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Browse more detail information about Malaria market report at: http://www.absolutereports.com/malaria-pipeline-review-h2-2016-10435018

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Malaria – Pipeline Review, H2 2016:

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actelion Ltd
  • Agilvax Inc
  • Akshaya Bio Inc.
  • Allergy Therapeutics Plc
  • Amura Holdings Limited
  • Anacor Pharmaceuticals, Inc.
  • Artificial Cell Technologies, Inc.
  • AstraZeneca Plc
  • Bharat Biotech International Limited
  • Callaghan Innovation Research Ltd.
  • Carna Biosciences, Inc.
  • CEL-SCI Corporation
     

Get a PDF Sample of Malaria Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435018

Key Topics Covered:
1.Introduction
2.Malaria Overview
3.Malaria Therapeutics Development
4.Pipeline Products for Malaria – Overview
5.Pipeline Products for Malaria – Comparative Analysis
6.Malaria – Therapeutics under Development by Companies
7.Malaria – Therapeutics under Investigation by Universities/Institutes
8.Malaria Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Malaria – Products under Development by Companies
13.Malaria – Products under Investigation by Universities/Institutes
14.Malaria – Companies Involved in Therapeutics Development
15.Malaria Drug Profiles
16.Malaria Dormant Projects
17.Malaria Discontinued Products
18.Malaria Featured News & Press Releases
And Continue…

Get Discount on Malaria Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435018

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Malaria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.